Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
ABVX
ABVX
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
ABVX News
Abivax Stock Potential and Risks Analysis
Apr 07 2026
Fool
Abivax's Promising Drug Candidate Faces Risks Amid Market Volatility
Apr 07 2026
NASDAQ.COM
Investment Outlook for Healthcare Stocks
Mar 26 2026
Fool
Biotech Companies Show Promising Clinical Progress
Mar 26 2026
NASDAQ.COM
Abivax CEO: No Rush for Deals Ahead of Key Trial
Mar 24 2026
seekingalpha
Abivax Reports €530.4M Cash Position for 2025
Mar 23 2026
seekingalpha
Investment Opportunities in Abivax and Nektar Therapeutics
Mar 20 2026
Fool
Abivax Viewed as a Potential Acquisition Target
Mar 20 2026
NASDAQ.COM
Abivax Shares Rise After Denying AstraZeneca Acquisition Report
Mar 12 2026
seekingalpha
AstraZeneca Poised to Acquire Abivax Amid Surge in Valuation
Mar 12 2026
Benzinga
Petco Reports Strong Q4 Results, Shares Surge
Mar 12 2026
Benzinga
Investing in Clinical-Stage Biotechs: Risks and Opportunities
Mar 10 2026
Fool
Reasons Behind Abivax's 1000% Stock Surge
Feb 27 2026
Fool
Abivax Presents New Findings on Obefazimod at ECCO Congress
Feb 21 2026
NASDAQ.COM
Abivax Presents Obefazimod's First Evidence of Anti-Fibrotic Activity
Feb 21 2026
Newsfilter
Eli Lilly's Decade of Market Dominance
Feb 11 2026
Fool
Show More News
